Genomics & Informatics

Korea Genome Organization (한국유전체학회)
권호 표지
DOI QR코드

DOI QR Code

Classification of Colon Cancer Patients Based on the Methylation Patterns of Promoters

  • Choi, Wonyoung (Department of Integrated OMICS for Biomedical Science, Graduate School, Yonsei University) ;
  • Lee, Jungwoo (Department of Integrated OMICS for Biomedical Science, Graduate School, Yonsei University) ;
  • Lee, Jin-Young (Department of Biochemistry, College of Life Science & Biotechnology, Yonsei University) ;
  • Lee, Sun-Min (Department of Biochemistry, College of Life Science & Biotechnology, Yonsei University) ;
  • Kim, Da-Won (Department of Integrated OMICS for Biomedical Science, Graduate School, Yonsei University) ;
  • Kim, Young-Joon (Department of Integrated OMICS for Biomedical Science, Graduate School, Yonsei University)
  • Received : 2015.11.25
  • Accepted : 2016.04.25
  • Published : 2016.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

Diverse somatic mutations have been reported to serve as cancer drivers. Recently, it has also been reported that epigenetic regulation is closely related to cancer development. However, the effect of epigenetic changes on cancer is still elusive. In this study, we analyzed DNA methylation data on colon cancer taken from The Caner Genome Atlas. We found that several promoters were significantly hypermethylated in colon cancer patients. Through clustering analysis of differentially methylated DNA regions, we were able to define subgroups of patients and observed clinical features associated with each subgroup. In addition, we analyzed the functional ontology of aberrantly methylated genes and identified the G-protein-coupled receptor signaling pathway as one of the major pathways affected epigenetically. In conclusion, our analysis shows the possibility of characterizing the clinical features of colon cancer subgroups based on DNA methylation patterns and provides lists of important genes and pathways possibly involved in colon cancer development.

Keywords

References

  1. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr, Kinzler KW. Cancer genome landscapes. Science 2013;339:1546-1558. https://doi.org/10.1126/science.1235122
  2. Kan Z, Jaiswal BS, Stinson J, Janakiraman V, Bhatt D, Stern HM, et al. Diverse somatic mutation patterns and pathway alterations in human cancers. Nature 2010;466:869-873. https://doi.org/10.1038/nature09208
  3. Schweiger MR, Barmeyer C, Timmermann B. Genomics and epigenomics: new promises of personalized medicine for cancer patients. Brief Funct Genomics 2013;12:411-421. https://doi.org/10.1093/bfgp/elt024
  4. Martincorena I, Campbell PJ. Somatic mutation in cancer and normal cells. Science 2015;349:1483-1489. https://doi.org/10.1126/science.aab4082
  5. Suva ML, Riggi N, Bernstein BE. Epigenetic reprogramming in cancer. Science 2013;339:1567-1570. https://doi.org/10.1126/science.1230184
  6. Baylin SB. DNA methylation and gene silencing in cancer. Nat Clin Pract Oncol 2005;2 Suppl 1:S4-S11. https://doi.org/10.1038/ncponc0354
  7. Kim MS, Lee J, Sidransky D. DNA methylation markers in colorectal cancer. Cancer Metastasis Rev 2010;29:181-206. https://doi.org/10.1007/s10555-010-9207-6
  8. Breuer K, Foroushani AK, Laird MR, Chen C, Sribnaia A, Lo R, et al. InnateDB: systems biology of innate immunity and beyond: recent updates and continuing curation. Nucleic Acids Res 2013;41:D1228-D1233. https://doi.org/10.1093/nar/gks1147
  9. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003;349:2042-2054. https://doi.org/10.1056/NEJMra023075
  10. Boland CR, Goel A. Microsatellite instability in colorectal cancer. Gastroenterology 2010;138:2073-2087.e3. https://doi.org/10.1053/j.gastro.2009.12.064
  11. Horsthemke B. Epimutations in human disease. Curr Top Microbiol Immunol 2006;310:45-59.
  12. Colussi D, Brandi G, Bazzoli F, Ricciardiello L. Molecular pathways involved in colorectal cancer: implications for disease behavior and prevention. Int J Mol Sci 2013;14:16365-16385. https://doi.org/10.3390/ijms140816365
  13. Yuan W, Lopez Bernal A. Cyclic AMP signalling pathways in the regulation of uterine relaxation. BMC Pregnancy Childbirth 2007;7 Suppl 1:S10. https://doi.org/10.1186/1471-2393-7-S1-S10
  14. Ritter SL, Hall RA. Fine-tuning of GPCR activity by receptor-interacting proteins. Nat Rev Mol Cell Biol 2009;10:819-830. https://doi.org/10.1038/nrm2803
  15. Agid Y, Buzsaki G, Diamond DM, Frackowiak R, Giedd J, Girault JA, et al. How can drug discovery for psychiatric disorders be improved? Nat Rev Drug Discov 2007;6:189-201. https://doi.org/10.1038/nrd2217
  16. Dufresne M, Seva C, Fourmy D. Cholecystokinin and gastrin receptors. Physiol Rev 2006;86:805-847. https://doi.org/10.1152/physrev.00014.2005
  17. Goodchild RE, Grundmann K, Pisani A. New genetic insights highlight 'old' ideas on motor dysfunction in dystonia. Trends Neurosci 2013;36:717-725. https://doi.org/10.1016/j.tins.2013.09.003
  18. Ligeti E, Welti S, Scheffzek K. Inhibition and termination of physiological responses by GTPase activating proteins. Physiol Rev 2012;92:237-272. https://doi.org/10.1152/physrev.00045.2010
  19. Dorsam RT, Gutkind JS. G-protein-coupled receptors and cancer. Nat Rev Cancer 2007;7:79-94. https://doi.org/10.1038/nrc2069
  20. Airaksinen MS, Saarma M. The GDNF family: signalling, biological functions and therapeutic value. Nat Rev Neurosci 2002;3:383-394. https://doi.org/10.1038/nrn812
  21. Hitchins MP. Constitutional epimutation as a mechanism for cancer causality and heritability? Nat Rev Cancer 2015;15:625-634. https://doi.org/10.1038/nrc4001